These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29406608)

  • 1. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities.
    Cortesi PA; Belli LS; Facchetti R; Mazzarelli C; Perricone G; De Nicola S; Cesana G; Duvoux C; Mantovani LG; Strazzabosco M;
    J Viral Hepat; 2018 Jul; 25(7):791-801. PubMed ID: 29406608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
    Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
    Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
    Njei B; McCarty TR; Fortune BE; Lim JK
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
    Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DMS; Chung RT; Chhatwal J
    Clin Gastroenterol Hepatol; 2018 Jan; 16(1):115-122.e10. PubMed ID: 28634131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
    Tapper EB; Hughes MS; Buti M; Dufour JF; Flamm S; Firdoos S; Curry MP; Afdhal NH
    Transplantation; 2017 May; 101(5):987-995. PubMed ID: 27495755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.
    Daniel KE; Said A
    Curr Gastroenterol Rep; 2018 Apr; 20(5):20. PubMed ID: 29623506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
    Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
    Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.
    Sandmann L; Dörge P; Wranke A; Vermehren J; Welzel TM; Berg CP; Grottenthaler JM; Weiss KH; Langel J; Sterneck M; von Wulffen M; Manns MP; Wedemeyer H; Hardtke S; von Hahn T
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1049-1056. PubMed ID: 30807443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
    Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
    J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
    Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
    Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
    Meunier L; Belkacemi M; Pageaux GP; Radenne S; Vallet-Pichard A; Houssel-Debry P; Duvoux C; Botta-Fridlund D; de Ledinghen V; Conti F; Anty R; Di Martino V; Debette-Gratien M; Leroy V; Gerster T; Lebray P; Alric L; Abergel A; Dumortier J; Besch C; Montialoux H; Samuel D; Duclos-Vallée JC; Coilly A
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.
    Choudhary NS; Saraf N; Saigal S; Rastogi A; Bhangui P; Thiagrajan S; Soin AS
    Indian J Gastroenterol; 2020 Dec; 39(6):539-543. PubMed ID: 33230754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients.
    Martini S; Tandoi F; Terzi di Bergamo L; Strona S; Lavezzo B; Sacco M; Maione F; Gonella F; Strignano P; Dell Olio D; Salizzoni M; Saracco GM; Romagnoli R
    Liver Transpl; 2017 Jul; 23(7):915-924. PubMed ID: 28422425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting.
    Perricone G; Duvoux C; Berenguer M; Cortesi PA; Vinaixa C; Facchetti R; Mazzarelli C; Rockenschaub SR; Martini S; Morelli C; Monico S; Volpes R; Pageaux GP; Fagiuoli S; Belli LS;
    Liver Int; 2018 Dec; 38(12):2170-2177. PubMed ID: 29750389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
    Gambato M; Lens S; Navasa M; Forns X
    J Hepatol; 2014 Nov; 61(1 Suppl):S120-31. PubMed ID: 25443340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.